These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

119 related items for PubMed ID: 15093584

  • 1. An autocrine loop for vascular endothelial growth factor is established in prostate cancer cells generated after prolonged treatment with interleukin 6.
    Steiner H, Berger AP, Godoy-Tundidor S, Bjartell A, Lilja H, Bartsch G, Hobisch A, Culig Z.
    Eur J Cancer; 2004 May; 40(7):1066-72. PubMed ID: 15093584
    [Abstract] [Full Text] [Related]

  • 2. Autocrine vascular endothelial growth factor signalling in breast cancer. Evidence from cell lines and primary breast cancer cultures in vitro.
    Weigand M, Hantel P, Kreienberg R, Waltenberger J.
    Angiogenesis; 2005 May; 8(3):197-204. PubMed ID: 16328160
    [Abstract] [Full Text] [Related]

  • 3. Prostate cancer cells (LNCaP) generated after long-term interleukin 6 (IL-6) treatment express IL-6 and acquire an IL-6 partially resistant phenotype.
    Hobisch A, Ramoner R, Fuchs D, Godoy-Tundidor S, Bartsch G, Klocker H, Culig Z.
    Clin Cancer Res; 2001 Sep; 7(9):2941-8. PubMed ID: 11555613
    [Abstract] [Full Text] [Related]

  • 4. A potential autocrine role for vascular endothelial growth factor in prostate cancer.
    Jackson MW, Roberts JS, Heckford SE, Ricciardelli C, Stahl J, Choong C, Horsfall DJ, Tilley WD.
    Cancer Res; 2002 Feb 01; 62(3):854-9. PubMed ID: 11830543
    [Abstract] [Full Text] [Related]

  • 5. Vascular endothelial growth factor acts in an autocrine manner in rhabdomyosarcoma cell lines and can be inhibited with all-trans-retinoic acid.
    Gee MF, Tsuchida R, Eichler-Jonsson C, Das B, Baruchel S, Malkin D.
    Oncogene; 2005 Dec 01; 24(54):8025-37. PubMed ID: 16116481
    [Abstract] [Full Text] [Related]

  • 6. Interleukin-6 undergoes transition from growth inhibitor associated with neuroendocrine differentiation to stimulator accompanied by androgen receptor activation during LNCaP prostate cancer cell progression.
    Lee SO, Chun JY, Nadiminty N, Lou W, Gao AC.
    Prostate; 2007 May 15; 67(7):764-73. PubMed ID: 17373716
    [Abstract] [Full Text] [Related]

  • 7. Prostate cancer cells generated during intermittent androgen ablation acquire a growth advantage and exhibit changes in epidermal growth factor receptor expression.
    Hobisch A, Fiechtl M, Sandahl-Sorensen B, Godoy-Tundidor S, Artner-Dworzak E, Ramoner R, Bartsch G, Culig Z.
    Prostate; 2004 Jun 01; 59(4):401-8. PubMed ID: 15065088
    [Abstract] [Full Text] [Related]

  • 8. Vascular endothelial growth factor C stimulates progression of human gastric cancer via both autocrine and paracrine mechanisms.
    Kodama M, Kitadai Y, Tanaka M, Kuwai T, Tanaka S, Oue N, Yasui W, Chayama K.
    Clin Cancer Res; 2008 Nov 15; 14(22):7205-14. PubMed ID: 19010837
    [Abstract] [Full Text] [Related]

  • 9. Autocrine vascular endothelial growth factor/vascular endothelial growth factor receptor-2 growth pathway represents a cyclooxygenase-2-independent target for the cyclooxygenase-2 inhibitor NS-398 in colon cancer cells.
    Kim SJ, Seo JH, Lee YJ, Yoon JH, Choi CW, Kim BS, Shin SW, Kim YH, Kim JS.
    Oncology; 2005 Nov 15; 68(2-3):204-11. PubMed ID: 16015035
    [Abstract] [Full Text] [Related]

  • 10. Tumor-induced activation of lymphatic endothelial cells via vascular endothelial growth factor receptor-2 is critical for prostate cancer lymphatic metastasis.
    Zeng Y, Opeskin K, Goad J, Williams ED.
    Cancer Res; 2006 Oct 01; 66(19):9566-75. PubMed ID: 17018613
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Interactions between sphingosine-1-phosphate and vascular endothelial growth factor signalling in ML-1 follicular thyroid carcinoma cells.
    Balthasar S, Bergelin N, Löf C, Vainio M, Andersson S, Törnquist K.
    Endocr Relat Cancer; 2008 Jun 01; 15(2):521-34. PubMed ID: 18509004
    [Abstract] [Full Text] [Related]

  • 14. Suppression of VEGF-mediated autocrine and paracrine interactions between prostate cancer cells and vascular endothelial cells by soy isoflavones.
    Guo Y, Wang S, Hoot DR, Clinton SK.
    J Nutr Biochem; 2007 Jun 01; 18(6):408-17. PubMed ID: 17142033
    [Abstract] [Full Text] [Related]

  • 15. Prostaglandin E2 induces vascular endothelial growth factor secretion in prostate cancer cells through EP2 receptor-mediated cAMP pathway.
    Wang X, Klein RD.
    Mol Carcinog; 2007 Nov 01; 46(11):912-23. PubMed ID: 17427962
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Interleukin-6 regulation of prostate cancer cell growth.
    Culig Z, Steiner H, Bartsch G, Hobisch A.
    J Cell Biochem; 2005 Jun 01; 95(3):497-505. PubMed ID: 15838876
    [Abstract] [Full Text] [Related]

  • 18. Hypoxia-induced epithelial VEGF-C/VEGFR-3 upregulation in carcinoma cell lines.
    Simiantonaki N, Jayasinghe C, Michel-Schmidt R, Peters K, Hermanns MI, Kirkpatrick CJ.
    Int J Oncol; 2008 Mar 01; 32(3):585-92. PubMed ID: 18292935
    [Abstract] [Full Text] [Related]

  • 19. Vascular endothelial growth factor contributes to prostate cancer-mediated osteoblastic activity.
    Kitagawa Y, Dai J, Zhang J, Keller JM, Nor J, Yao Z, Keller ET.
    Cancer Res; 2005 Dec 01; 65(23):10921-9. PubMed ID: 16322239
    [Abstract] [Full Text] [Related]

  • 20. [Autocrine stimulation of receptor-tyrosine kinases (RTK) in human tumor cell lines in vitro: therapeutic implications].
    Gaumann A, Groot M, Drexler HC, Breier G.
    Verh Dtsch Ges Pathol; 2003 Dec 01; 87():232-9. PubMed ID: 16888917
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 6.